Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XDH | P47989 | 2/20 | 0.39 |
| ▸ | PNP | P00491 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | TYMP | P19971 | 1/20 | 0.33 |
| ▸ | FABP6 | P51161 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | CDK4 | P11802 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14217450 | 0.81 | TYMP (0.43) | XDHPNPCYP3A4BLMHSD17B10 | |
| SCHEMBL172129 | 0.75 | ALDH1A1 (0.37) | ALDH1A1L3MBTL1MAPT | |
| SCHEMBL8531415 | 0.74 | KDM5B (0.33) | XDHPNPCYP3A4BLMHSD17B10 | |
| SCHEMBL4070047 | 0.71 | TYMS (0.38) | XDHCYP3A4BLMNPSR1ALDH1A1 | |
| SCHEMBL9879126 | 0.70 | L3MBTL1 (0.46) | XDHPNPNPSR1L3MBTL1BACE1 | |
| SCHEMBL9965294 | 0.70 | HSD17B10 (0.46) | PNPCYP3A4HSD17B10NPSR1CYP1A2 | |
| SCHEMBL27942625 | 0.70 | MAPK1 (0.39) | XDHHSD17B10NPSR1ALDH1A1BACE1 | |
| SCHEMBL11988254 | 0.69 | HSD17B10 (0.45) | CYP3A4HSD17B10NPSR1CYP1A2ALDH1A1 | |
| SCHEMBL28460640 | 0.69 | HSD17B10 (0.42) | CYP3A4HSD17B10NPSR1CYP1A2ALDH1A1 | |
| SCHEMBL215067 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114716961-B | Self-complementary quadruple hydrogen bond supermolecule hot melt adhesive and synthesis method thereof | 郑州大学 | 2023-06-23 | — | — | CN | disclosed |
| CN-114716961-A | Self-complementary quadruple hydrogen bond supramolecular hot melt adhesive and synthesis method thereof | 郑州大学 | 2022-07-08 | — | — | CN | disclosed |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | NAGARAHNAM DHANAPALAN (US) | 2012-11-29 | — | — | US | disclosed |
| EP-1470121-B1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER HEALTHCARE LLC (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20120053179-A1 | Rho-Kinase Inhibitors | NAGARATHNAM DHANAPALAN (US) | 2012-03-01 | — | — | US | disclosed |
| EP-1470122-B1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORP (US) | 2007-12-19 | — | — | EP | disclosed |
| US-20050209261-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-22 | — | — | US | disclosed |
| US-6943172-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-09-13 | — | — | US | disclosed |
| US-20050192304-A1 | Rho-kinase inhibitors | BAYER HEALTHCARE LLC | 2005-09-01 | — | — | US | disclosed |
| US-6924290-B2 | Rho-kinase inhibitors | BAYER PHARMACEUTICALS CORPORATION (US) | 2005-08-02 | — | — | US | disclosed |
| EP-1470122-A1 | RHO-KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-10-27 | — | — | EP | disclosed |
| EP-1470121-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | Bayer Pharmaceuticals Corporation (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | BAYER CORPORATION | 2004-01-01 | — | — | US | disclosed |
| US-20040002507-A1 | Rho-kinase inhibitors | BAYER CORPORATION (US) | 2004-01-01 | — | — | US | disclosed |
| WO-2003062227-A1 | RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
| WO-2003062225-A1 | PYRIMIDINE DERIVATIVES AS RHO-KINASE INHIBITORS | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002507-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | XDH 598/4885PNP 1050/4885CYP3A4 2878/4885 |
| US-20120053179-A1 | Rho-Kinase Inhibitors | CIT, ROCK1, ROCK2 | XDH 598/4885PNP 1050/4885CYP3A4 2878/4885 |
| US-20050209261-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | XDH 598/4885PNP 1050/4885CYP3A4 2878/4885 |
| US-20040002508-A1 | Antitumor agents; anticancer agents; sexual disorders; cardiovascular disorders | CIT, ROCK1, RHOT2 | XDH 564/4885PNP 1179/4885CYP3A4 2456/4885 |
| US-20120302587-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | XDH 598/4885PNP 1050/4885CYP3A4 2878/4885 |
| US-20050192304-A1 | Rho-kinase inhibitors | CIT, ROCK1, ROCK2 | XDH 598/4885PNP 1050/4885CYP3A4 2878/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.